Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy

Overview

cited authors

Garon, Edward B.; Scagliotti, Giorgio Vittorio; Gautschi, Oliver; Reck, Martin; Thomas, Michael; Iglesias Docampo, Lara; Kalofonos, Haralabos; Kim, Joo-Hang; Gans, Steven; Brustugun, Odd Terje; Orlov, Sergey V.; Carter, Gebra Cuyun; Zimmermann, Annamaria H.; Oton, Ana B.; Alexandris, Ekaterine; Lee, Pablo; Wolff, Katharina; Stefaniak, Victoria Jennifer; Socinski, Mark A.; Perol, Maurice

authors

Socinski, Mark A., MD

Publication Date

January 1, 2020

webpage

Web of Science

published in

ESMO OPEN Journal

301 E Princeton St., Orlando, FL 32804 | FH.RAS@AdventHealth.com | 407-200-2901

The information on this website is not a substitute for examination, diagnosis, and medical care provided by a licensed and qualified health professional. Please consult your physician before undertaking any form of medical treatment and/or adopting any exercise program or dietary guidelines. If you think you may have a medical emergency, call your physician or 911 immediately. AdventHealth Research Institute reserves the right to add, remove or edit content on this page at its sole discretion.